Biotechs Raise Billions to Let AI Design Drugs From Scratch
Nature Biotechnology surveys a shift that's already well underway: AI is no longer just screening candidate molecules, it's generating entirely new ones from the ground up. The massive funding rounds pouring into this space signal that investors are betting on drastically shorter R&D cycles than the traditional ten-to-fifteen-year timeline.
practitioners › Nature Biotechnology, May 26, 2026 feature on AI-driven programmable therapeutic design.
www.nature.com →